Trial Profile
A Phase II Study Evaluating FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms OPTIPRIME
- 16 Aug 2023 Planned End Date changed from 1 Nov 2024 to 1 Dec 2024.
- 16 Aug 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Apr 2024.
- 16 Aug 2023 Status changed from recruiting to active, no longer recruiting.